Importance of novel sequence alterations in the FHIT gene on formation of breast cancer

Tumori

Volumn 93, Issue 6, 2007, Pages 597-603

  Çeçener, Gülşah ^a   Egeli, Ünal ^a   Tunca, Berrin ^a   Taşdelen, Ismet ^a   Tolunay, Şahsine ^a   Bilgel, Nazan ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Benign breast diseases; Exonic splicing enhancers; FHIT gene; Malignant breast disease; Novel mutations; Single strand conformational polymorphism

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PRIMER DNA;

ADOLESCENT; ADULT; ARTICLE; BENIGN TUMOR; BREAST CANCER; CARCINOGENESIS; CODON; EVALUATION; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 38549172054     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300614     Document Type: Article

References (42)

1. Sozzi G, Veronese M, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM: The FHIT gene At 3p14.2 is abnormal in lung cancer. Cell, 85: 17-26, 1996.
2. Huebner K, Croce CM: Cancer and FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer, 88: 1501-1505, 2003.
3. Çeçener G, Egeli Ü, Taşdelen İ, Tunca B, Duman H and Kizil A: Common fragile sites expression and genetic predisposition to breast cancer. Teratogen Carcinogen Mutagen, 18: 279-291, 1998.
4. Ishii H, Dumon.Kr, Vecchione A, Fong Y, Baffa R, Huebner K, Croce CM: Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA, 286: 2441-2449, 2001.
5. Huebner K, Sozzi G, Brenner C, Pierotti MA, Croce CM: FHIT loss in lung cancer: diagnostic and therapeutic implications. Adv Oncol, 15: 3-10, 1999.
6. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD, Gazdar AF: Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res, 57: 3664-3668, 1997.
7. Kannan K, Krishnamurthy J, Feng J, Nakajima T, Tsuchida N, Shanmugam G: Mutation profile of the p53, FHIT, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Int J Oncol, 17: 1031-1035, 2000.
8. Ohta M, Inove H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84: 587-597, 1996.
9. Gemma A, Hagiwarn K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP, Harris CC: FHIT mutations in human primary gastric cancer. Cancer Res, 57: 1435-1437, 1997.
10. ESEfinder program. Available at: http://rulai.cshl.edu/tools/ESE (accessed December 2007).
11. Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI: An FHIT tumor suppressor gene? Genes Chromosomes Cancer, 21: 281-289, 1998.
12. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res, 58: 5032-5037, 1998.
13. Huebner K, Croce C: FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer, 1: 214-221, 2001.
14. Fong KM, Biesterveld EJ, Virmania A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD: FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer related FHIT cDNA splicing aberrations. Cancer Res, 57: 2256-2267, 1997.
15. Yoshino K, Enomoto T, Nakamura T, Nakashima R, Wada H, Saitoh J, Noda K, Murata Y: Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer, 76: 176-181, 1998.
16. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW: Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer, 78: 766-774, 1998.
17. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res, 57: 504-512, 1997.
18. Deng YF, Tian F, Lu YD, Chen ZC, Xie DH, Yang XM, Shao XY: Mutation and abnormal expression of the fragile histidine triad gene in nasopharyngeal carcinoma. Laryngoscope, 111: 1589-1592, 2001.
19. Zhao XR, Kang LC, Zhou YS, Jia YX, Chen Z, Kang SH, Li WM, Zhao M, Cui JT, Sun AL, Lu YY: Mutations of fragile histidine triad gene in Peutz-Jeghers syndrome and canceration. Ai Zheng, 22: 50-54, 2003.
20. Matsuyama A, Croce CM, Huebner K: Common fragile genes. Eur J Histochem, 48: 29-36, 2004.
21. Krawczak M, Reiss J, Cooper DN: The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet, 90: 41-54, 1992.
22. Kalnina Z, Zayakin P, Silina K, Line A: Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer, 42: 342-357, 2005.
23. Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK: Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat, 27: 427-435, 2006.
24. Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D: BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat, Mutation in Brief#553: Online, 2002.
25. Zi X, Szabo C, Chopin S, Suter N, Wang QS, Ostrander EA, Sinilnikova OM, Lenoir GM, Goldgar D, Shi YR: BRCA1 and BRCA2 sequence variants in Chinese breast cancer families. Hum Mutat, Mutation in Brief#554: Online, 2002.
26. Wang J, Smith PJ, Krainer AR, Zang MQ: Distribution of SR protein exonic splicing enhancer motifs human protein-coding genes. Nucleic Acids Res, 33: 5053-5062, 2005.
27. Fackenthal JD, Cartegni L, Krainer AR, Olopade OI: BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet, 71: 625-631, 2002.
28. Yang Y, Swaminathan S, Martin BK, Sharan SK: Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Hum Mol Genet, 12: 2121-2131, 2003.
29. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acid Res, 31: 3568-3571, 2003.
30. Fu XD: The superfamily of arginine/serine-rich splicing factors. RNA, 1: 663-680, 1995.
31. Valcarcel J, Green MR: The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem Sci, 21: 296-301, 1996.
32. Liu HX, Zhang M, Krainer AR: Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev, 12: 1998-2012, 1998.
33. Liu HX, Chew SL, Cartegni L, Zhang MQ, Krainer AR: Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol Cell Biol, 20: 1063-1071, 2000.
34. Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM, Lenoir GM: A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet, 62: 713-715, 1998.
35. Liu HX, Cartegni L, Zhang MQ, Krainer AR: A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet, 27: 55-58, 2001.
36. McIver B, Grebe SK, Wang L, Hay ID, Yokomizo A, Liu W, Goellner JR, Grant CS, Smith DI, Eberhardt NL: FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin Endocrinol, 52: 749-757, 2000.
37. Lee SH, Kim CJ, Park HK, Koh JW, Cho MH, Baek MJ, Lee MS: Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med, 33: 124-130, 2001.
38. Kraggerud SM, Aman P, Holm R, Stenwig AE, Fossa SD, Nesland JM, Lothe RA: Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis. Cancer Res, 62: 512-517, 2002.
39. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y: Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res, 67: 1177-1182, 2000.
40. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N, Kawasaki H: Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology, 61: 205-211, 2001.
41. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Munoz N, Cho KR: Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res, 6: 3505-3510, 2000.
42. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, Huebner K: Concordant loss of fragile gene expression early in breast cancer development. Pathol Int, 8: 471-478, 2005.